You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

early relapsing multiple sclerosis

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo for Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • New Haven, Connecticut
  • +9 more
Jan 17, 2023

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

Tysabri in Early Relapsing Remitting Multiple Sclerosis

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Amadora, Portugal
  • +17 more
Apr 12, 2022

Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

Recruiting
  • Relapse Remitting Multiple Sclerosis
  • Chandler, Arizona
  • +16 more
Jan 13, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Sweden (Rituximab, Dimethyl fumarate, Sodium Chloride solution)

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • Borås, Sweden
  • +16 more
Oct 11, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Aggressive Therapy or Traditional Therapy
  • Birmingham, Alabama
  • +51 more
Jan 23, 2023

Relapsing Multiple Sclerosis, Multiple Sclerosis Trial (Placebo, Pirtobrutinib)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis
  • (no location specified)
Oct 24, 2023

Multiple Sclerosis Trial in Genova (7-day Fasting-Mimicking Diet (7-DAY FMD))

Active, not recruiting
  • Multiple Sclerosis
  • 7-day Fasting-Mimicking Diet (7-DAY FMD)
  • Genova, Italy
    Ospedale San Martino
Sep 8, 2023

Ofatumumab in Portuguese Multiple Sclerosis Patients

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 30, 2023

Lesion Load and Location in Relation to Cognition, Fatigue and

Completed
  • Relapsing Remitting Multiple Sclerosis
  • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
  • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
  • Assiut, Egypt
    Eman Khedr
Oct 27, 2022

Relapsing Remitting Multiple Sclerosis Trial in Glasgow (Clinical assessment)

Enrolling by invitation
  • Relapsing Remitting Multiple Sclerosis
  • Clinical assessment
  • Glasgow, United Kingdom
    Clinical Research Facility
Jul 20, 2022

Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • PIPE-307 Dose A
  • +2 more
  • (no location specified)
Oct 9, 2023

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Cardiometabolic Health in Multiple Sclerosis

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • Diepenbeek, Limburg, Belgium
      Hasselt University
    Mar 1, 2023

    Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • West Orange, New Jersey
      Kessler Foundation
    Oct 12, 2022

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023

    Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

    Not yet recruiting
    • Multiple Sclerosis
    • Magnetic Resonance Imaging
    • +2 more
    • Montpellier, France
      Neurology Department, Hopital Gui de Chauliac
    Jul 18, 2023

    Multiple Sclerosis, Relapsing-Remitting Trial in Elazig (Reiki)

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Reiki
    • Elazıg, Turkey
      Firat University
    Nov 8, 2023

    Multiple Sclerosis Trial (Frexalimab, Teriflunomide, Placebo infusion)

    Not yet recruiting
    • Multiple Sclerosis
    • (no location specified)
    Nov 15, 2023

    Assess New Participant's Perspectives Beyond Clinical Efficacy

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • (no location specified)
      Nov 7, 2023

      Bafiertam Treatment In Routine Clinical Practice

      Enrolling by invitation
      • Relapsing Remitting Multiple Sclerosis
      • Monomethyl Fumarate
      • West Hollywood, California
      • +1 more
      Aug 3, 2023

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

        Not yet recruiting
        • Relapsing-remitting Multiple Sclerosis (RRMS)
          • (no location specified)
          Apr 11, 2023

          Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

          Not yet recruiting
          • Relapsing Multiple Sclerosis
          • No intervention
          • (no location specified)
          Nov 16, 2023

          Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

          Active, not recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Multiple Sclerosis, Secondary Progressive
          • Tokyo, Japan
            National Center of Neurology and Psychiatry
          Sep 28, 2022